Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) demonstrated statistically significant improvements in trough Forced Expiratory Volume (FEV1) at 24 weeks compared to all other triple therapy comparators, except for umeclidinium combined with fluticasone and vilanterol (UMEC + FF/VI).
• At 24 weeks, FF/UMEC/VI showed statistically significant reductions in the annualized rate of combined moderate or severe exacerbations compared to single-inhaler budesonide/glycopyrronium bromide/formoterol (BUD/GLY/FOR) and UMEC + FF/VI.
• FF/UMEC/VI also exhibited improvements in mean St. George's Respiratory Questionnaire (SGRQ) scores and a significant reduction in rescue medication use compared to BUD/GLY/FOR at 24 weeks.
• The studies did not provide detailed information on specific safety outcomes or adverse effects related to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI).
• No significant safety concerns or adverse effects were reported for FF/UMEC/VI, budesonide/glycopyrronium bromide/formoterol (BUD/GLY/FOR), or budesonide/glycopyronium/formoterol fumarate metered dose inhaler (BGF MDI).
• The studies focused on adults aged at least 40 years with moderate to very severe chronic obstructive pulmonary disease (COPD), but no specific findings relevant to particular subgroups, such as age groups, gender, or comorbid conditions, were detailed.